This article is more than 5 years old. Information may no longer be current.
EyeGate Pharma completes follow-up for phase 2 dry eye study
WALTHAM, Mass. — EyeGate Pharma has fully enrolled and completed all follow-up visits for patients participating in its phase 2 safety and efficacy trial of a corticosteroid solution and ocular drug delivery system for treating dry eye syndrome, the company announced in a press release.
The single-center, randomized, double-masked, placebo-controlled study evaluated the safety and efficacy of a corticosteroid solution, called EGP-437, administered by the EyeGate II Delivery System at two dose levels administered twice over a 3-week period among 89 patients.
EGP-437 is also being evaluated in a phase 1/2 clinical study for severe uveitis. These trials represent the first U.S. studies to employ ocular iontophoresis technology to deliver an active compound into the eye, the release said.
EyeGate Pharma plans to release the results of the dry eye study in the second quarter, the release said.